|
|
Article: Scientist Expects Veridien's Viraguard to be Effective Against Anthrax Bacteria and Smallpox Virus.
- Article from:
- Business Wire
- Article date:
- October 25, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Environment, Health & Medical Writers
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Oct. 25, 2001
Veridien Corporation (OTCBB:VRDE) is pleased to publish the following opinion of Thomas C. Laipply, M.D., FCAP, FIAP, a Pathologist and Director of Molecular Tissue Pathology with Nichols Institute-Quest Diagnostics, in San Juan Capistrano, California, and a member of the Veridien Corporation Scientific Advisory Board:
"Based on my medical knowledge and the already established high effectiveness of Viraguard(R) as an antimicrobial against pathogenic bacteria and viruses and common fungi, it is my expectation that Viraguard(R) would prove ...